Figure 6.

Cell entry through SLAM but not CD46 sustains efficient MV^vac2NIS oncolysis. (a) Flow cytometry analysis of surface expression of MV receptors nectin-4, CD46, and SLAM on Granta-519 cells (left, representative experiment) and the effects of receptor-blocking antibodies on MV^vac2GFP infection of Granta-519 cells in vitro, as measured by flow cytometry for GFP⁺ cells (right, data are given as mean ± SD; n = 3). (b) Cell-associated virus titers for MV^vac2NIS, MV^vac2NIS^CD46, and MV^vac2NIS^SLAM 48 hours after infection at an multiplicity of infection (MOI) of 0.03 in Granta-519 cells. Data are given as mean ± SD; n = 3. (c) Mean tumor response curves, as measured externally with calipers, for animals treated with IV vehicle or the three viruses indicated. Data points represent means (n = 5), error bars were excluded for clarity. (d) Kaplan–Meier survival curve for animals treated IV with vehicle or the three viruses indicated. (e) U-SPECTII/CT quantification of tumor volume (left) and isotope uptake (right) within primary and metastatic tumors 10 days after IV administration of vehicle or the three viruses indicated. Data points represent individual tumors, lines indicate means. c–e display data from a single experiment. IV, intravenously; MV, measles virus; SPECT, single photon emission computed tomography.